AMRX vs UBER · P/E 44, rev $2.79B vs P/E 18, rev $52.02B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Uber Technologies Inc (UBER) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Uber Technologies Inc (UBER) is a software - application company listed on NYSE. It is led by Dara Khosrowshahi.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported UBER revenue for 2025-12-31 was $52.02B. Net income was $10.05B. Revenue was up 18.3% from 2024-12-31 to 2025-12-31. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
Not investment advice. Open the AMRX and UBER stock pages for the full models.
Not investment advice.